Virtual screening on an α-helix to β-strand switchable region of the FGFR2 extracellular domain revealed positive and negative modulators

Proteins: Structure, Function and Bioinformatics

Volumn 82, Issue 11, 2014, Pages 2982-2997

  Diaz, Constantino ^a   Herbert, Corentin ^a   Vermat, Thierry ^a   Alcouffe, Chantal ^a   Bozec, Tanguy ^a   Sibrac, David ^a   Herbert, Jean Marc ^a   Ferrara, Pascual ^a   Bono, Françoise ^a   Ferran, Edgardo ^a  

^a SANOFI   (France)

Author keywords

Allosteric modulation; Ambivalence; Bioinformatics; Disease; Drug discovery; Mutation; Protein structure; Receptor function; Secondary structure; Virtual screening

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FGFR2 PROTEIN, HUMAN; FGFR2 PROTEIN, RAT; FIBROBLAST GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ALGORITHM; ALPHA HELIX; AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAP KINASE ASSAY; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; RAT; ANIMAL; CELL LINE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; LIBRARY; METABOLISM; MOLECULAR GENETICS; MUTATION; NEOPLASM; PHOSPHORYLATION; PROCEDURES; PROTEIN TERTIARY STRUCTURE; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

ALGORITHMS; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CELL PROLIFERATION; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HUMANS; LIBRARIES, DIGITAL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, FIBROBLAST GROWTH FACTOR; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION;

EID: 84937570315     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24657     Document Type: Article

References (72)

1. Kabsch W, Sander C. On the use of sequence homologies to predict protein structure: identical pentapeptides can have completely different conformations. Proc Natl Acad Sci USA 1984;81:1075-1078.
2. Cohen BI, Presnell SR, Cohen FE. Origins of structural diversity within sequentially identical hexapeptides. Protein Sci 1993;2:2134-2145.
3. Mezei M. Chameleon sequences in the PDB. Protein Eng 1998;11:411-414.
4. Yoon S, Jung H. Analysis of chameleon sequences by energy decomposition on a pairwise per-residue basis. Protein J 2006;25:361-368.
5. Guo JT, Jaromczyk JW, Xu Y. Analysis of chameleon sequences and their implications in biological processes. Proteins 2007;67:548-558.
6. Minor JrDL, Kim PS. Context-dependent secondary structure formation of a designed protein sequence. Nature 1996;380:730-734.
7. Anderson WJ, Van Dorn LO, Ingram WM, Cordes MHJ. Evolutionary bridges to new protein folds: design of C-terminal Cro protein chameleon sequences. Protein Eng Des Sel 2011;24:765-771.
8. Takano K, Katagiri Y, Mukaiyama A, Chon H, Matsumura H, Koga Y, Kanaya S. Conformational contagion in a protein: structural properties of a chameleon sequence. Proteins 2007; 68:617-625.
9. Tan S, Richmond TJ. Crystal structure of the yeast MATα2/MCM1/DNA ternary complex. Nature 1998;391:660-666.
10. Troffer-Charlier N, Cura V, Hassenboehler P, Moras D, Cavarelli J. Functional insights from structures of coactivator-associated arginine methyltransferase 1 domains. EMBO J 2007;26:4391-4401.
11. Mapelli M, Musacchio A. MAD contortions: conformational dimerization boosts spindle checkpoint signalling. Curr Opin Struct Biol 2007;17:716-725.
12. Luo X, Yu H. Protein metamorphosis: the two-state behavior of Mad2. Structure 2008;16:1616-1625.
13. Littler DR, Harrop SJ, Fairlie WD, Brown LJ, Pankhurst GJ, Pankhurst S, DeMaere MZ, Campbell TJ, Bauskin AR, Tonini R, Mazzanti M, Breit SN, Curmi PMG. The intracellular chloride ion channel protein CLIC1 undergoes a redox-controlled structural transition. J Biol Chem 2004;279:9298-9305.
14. Burmann BM, Knauer SH, Sevostyanova A, Schweimer K, Mooney RA, Landick R, Artsimovitch I, Rösch P. An α helix to β barrel domain switch transforms the transcription factor RfaH into a translation factor. Cell 2012;150:291-303.
15. Le Maire A, Teyssier C, Erb C, Grimaldi M, Alvarez S, de Lera AR, Balaguer P, Gronemeyer H, Royer CA, Germain P, Bourguet W. A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor. Nat Struct Mol Biol 2010;17:801-807.
16. Littler DR, Harrop SJ, Goodchild SC, Phang JM, Mynott AV, Jiang L, Valenzuela SM, Mazzanti M, Brown LJ, Breit SN. The enigma of the CLIC proteins: ion channels, redox proteins, enzymes, scaffolding proteins? FEBS Lett 2010;584:2093-2101.
17. Skinner JJ, Wood S, Shorter J, Englander SW, Black BE. The Mad2 partial unfolding model: regulating mitosis through Mad2 conformational switching. J Cell Biol 2008;183:761-768.
18. Kupker L, Hinrichs W, Groschup MH. Prion protein misfolding. Curr Mol Med 2009;9:826-835.
19. Diaz-Espinoza R, Soto C. High-resolution structure of infectious prion protein: the final frontier. Nat Struct Mol Biol 2012;19:370-377.
20. Büttner A, Cottin T, Xu J, Tzagkaroulaki L, Giannis A. Serotonin derivatives as a new class of non-ATP-competitive receptor tyrosine kinase inhibitors. Bioorgan Med Chem 2010;18:3387-3402.
21. Eglen R, Reisine T. Drug discovery and the human kinome: recent trends. Pharmacol Therapeut 2011;130:144-156.
22. Squires M, Ward G, Saxty G, Berdini V, Cleasby A, King P, Angibaud P, Perera T, Fazal L, Ross D, Griffiths Jones C, Madin A, Benning RK, Vickerstaffe E, O'Brien A, Frederickson M, Reader M, Hamlett C, Batey MA, Rich S, Carr M, Miller D, Feltell R, Thiru A, Bethell S, Devine LA, Graham BL, Pike A, Cosme J, Lewis EJ, Freyne E, Lyons J, Irving J, Murray C, Newell DR, Thompson NT. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models. Mol Cancer Ther 2011;10:1542-1552.
23. Garnier J, Osguthorpe DJ, Robson B. Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. J Mol Biol 1978;120:97-120.
24. Garnier J, Gibrat JF, Robson B. GOR method for predicting protein secondary structure from amino acid sequence. Method Enzymol 1996;266:540-553.
25. Sen TZ, Jernigan RL, Garnier J, Kloczkowski A. GOR V server for protein secondary structure prediction. Bioinformatics 2005;21:2787-2788.
26. Kirshenbaum K, Young M, Highsmith S. Predicting allosteric switches in myosins. Prot Sci 1999;8:1806-1815.
27. Young M, Kirshenbaum K, Dill KA, Highsmith S. Predicting conformational switches in proteins. Prot Sci 1999;8:1752-1764.
28. Hansen MB, Ruizendaal L, Löwik DWPM, van Hest JCM. Switchable peptides. Drug Discov Today Technol 2009;6:1-4 (e33-e39).
29. Georgieva ER, Narvaez AJ, Hedin N, Gräslund A. Secondary structure conversions of Mycobacterium tuberculosis ribonucleotide reductase protein R2 under varying pH and temperature conditions. Biophys Chem 2008;137:43-48.
30. Tuinstra RL, Peterson FC, Kutlesa S, Elgin ES, Kron MA, Volkman BF. Interconversion between two unrelated protein folds in the lymphotactin native state. Proc Natl Acad Sci USA 2008;105:5057-5062.
31. Gehenn K, Pipkorn R, Reed J. Successful design and synthesis of a polarity-triggered β --> α conformational switch using the side chain interaction index (SCII) as a measure of local structural stability. Biochemistry 2004;43:607-612.
32. Broncel M, Wagner SC, Paul K, Hackenberger CPR, Koksch B. Towards understanding secondary structure transitions: phosphorylation and metal coordination in model peptides. Org Biomol Chem 2010;8:2575-2579.
33. Abel K, Yoder MD, Hilgenfeld R, Jurnak F. An α to β conformational switch in EF-Tu. Structure 1996;4:1153-1159.
34. Anderson TA, Cordes MHJ, Sauer RT. Sequence determinants of a conformational switch in a protein structure. Proc Natl Acad Sci USA 2005;102:18344-18349.
35. Alexander PA, He Y, Chen Y, Orban J, Bryan PN. A minimal sequence code for switching protein structure and function. Proc Natl Acad Sci USA 2009;106:21149-21154.
36. He Y, Chen Y, Alexander PA, Bryan PN, Orban J. Mutational tipping points for switching protein folds and functions. Structure 2012;20:283-291.
37. Ronga L, Palladino P, Ragone R, Benedetti E, Rossi F. A thermodynamic approach to the conformational preferences of the 180-195 segment derived from the human prion protein α2-helix. J Pept Sci 2009;15:30-35.
38. Weinzierl ROJ. The nucleotide addition cycle of RNA polymerase is controlled by two molecular hinges in the Bridge Helix domain. BMC Biol 2010;8:134.
39. Ambroggio XI, Kuhlman B. Computational design of a single amino acid sequence that can switch between two distinct protein folds. J Am Chem Soc 2006;128:1154-1161.
40. Stauber DJ, DiGabriele AD, Hendrickson WA. Structural interactions of fibroblast growth factor receptor with its ligands. Proc Natl Acad Sci USA 2000;97:49-54.
41. Herbert C, Schieborr U, Saxena K, Juraszek J, De Smet F, Alcouffe C, Bianciotto M, Saladino G, Sibrac D, Kudlinzki D, Sreeramulu S, Brown A, Rigon P, Herault JP, Lassalle G, Blundell TL, Rousseau F, Gils A, Schymkowitz J, Tompa P, Herbert JM, Carmeliet P, Gervasio FL, Schwalbe H, Bono F. Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell 2013;23:489-501.
42. Venkatachalam CM, Jiang X, Oldfield T, Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Mod 2003;21:289-307.
43. Montes M, Miteva MA, Villoutreix BO. Structure-based virtual ligand screening with LigandFit: pose prediction and enrichment of compound collections. Proteins 2007;68:712-725.
44. Diaz C, Labit-Le Bouteiller C, Yvon S, Cambon-Kernéis A, Roasio A, Jamme MF, Aries A, Feuillerat C, Perret E, Guette F, Dieu P, Miloux B, Albène D, Hasel N, Kaghad M, Ferran E, Lupker J, Ferrara P. A strategy combining differential low-throughput screening and virtual screening (DLS-VS) accelerating the discovery of new modulators for the orphan GPR34 receptor. Mol Inf 2013;32:213-229.
45. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-253.
46. Katoh M. Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics. Expert Rev Anticancer Ther 2010;10:1375-1379.
47. Jain VK, Turner NC. Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. Breast Cancer Res 2012;14:208.
48. Bhattacharjee N, Biswas P. Statistical analysis and molecular dynamics simulations of ambivalent alpha-helices. BMC Bioinform 2010;11:519.
49. Robertson SC, Meyer AN, Hart KC, Galvin BD, Webster MK, Donoghue DJ. Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. Proc Natl Acad Sci USA 1998;95:4567-4572.
50. Lajeunie E, Heuertz S, El Ghouzzi V, Martinovic J, Renier D, Le Merrer M, Bonaventure J. Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. Eur J Hum Genet 2006;14:289-298.
51. Anderson J, Burns HD, Enriquez-Harris P, Wilkie AOM, Heath JK. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet 1998;7:1475-1483.
52. Yu K, Herr AB, Waksman G, Ornitz DM. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci USA 2000;97:14536-14541.
53. Del Sol A, Tsai CJ, Ma B, Nussinov R. The origin of allosteric functional modulation: multiple pre-existing pathways. Structure 2009;17:1042-1050.
54. Korb O, Olsson TSG, Bowden SJ, Hall RJ, Verdonk ML, Liebeschuetz JW, Cole JC. Potential and limitations of ensemble docking. J Chem Inf Model 2012;52:1262-1274.
55. Rao S, Sanschagrin PC, Greenwood JR, Repasky MP, Sherman W, Farid R. Improving database enrichment through ensemble docking. J Comput Aided Mol Des 2008;22:621-627.
56. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008;68:2340-2348.
57. Bai A, Meetze K, Vo NY, Kollipara S, Mazsa EK, Winston WM, Weiler S, Poling LL, Chen T, Ismail NS, Jiang J, Lerner L, Gyuris J, Weng Z. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res 2010;70:7630-7639.
58. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Clackson T, Rivera VM. Ponatinib (AP24534), a multitargeted Pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012;11:690-699.
59. Guagnano V, Kauffmann A, Wohrle S, Stamm C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, Chen Z, Wilson CJ, Bordas V, Le Douget M, Gaither LA, Borawski J, Monahan JE, Venkatesan K, Brummendorf T, Thomas DM, Garcia-Echeverria C, Hofmann F, Sellers WR, Graus-Porta D. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2012;2:1118-1133.
60. Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, Tjwa M, Alcouffe C, Ny A, Bianciotto M, Jonckx B, Murakami M, Lanahan AA, Michielsen C, Sibrac D, Dol-Gleizes F, Mazzone M, Zacchigna S, Herault JP, Fischer C, Rigon P, Ruiz de Almodovar C, Claes F, Blanc I, Poesen K, Zhang J, Segura I, Gueguen G, Bordes MF, Lambrechts D, Broussy R, van de Wouwer M, Michaux C, Shimada T, Jean I, Blacher S, Noel A, Motte P, Rom E, Rakic JM, Katsuma S, Schaeffer P, Yayon A, Van Schepdael A, Schwalbe H, Gervasio FL, Carmeliet G, Rozensky J, Dewerchin M, Simons M, Christopoulos A, Herbert JM, Carmeliet P. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 2013;23:477-488.
61. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007;282:26687-26695.
62. Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH, Eliseenkova AV, Green D, Schlessinger J, Hubbard SR. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998;17:5896-5904.
63. Jacoboni I, Martelli PL, Fariselli P, Compiani M, Casadio R. Prediction of protein segments with the same aminoacid sequence and different secondary structure: a benchmark for predictive methods. Proteins 2000;41:535-544.
64. Cheng J, Li J, Wang Z, Eickholt J, Deng X. The MULTICOM toolbox for protein structure prediction. BMC Bioinform 2012;13:65.
65. Boden M, Bailey TL. Identifying sequence regions undergoing conformational changes via predicted continuum secondary structure. Bioinformatics 2006;22:1809-1814.
66. Kuznetsov IB. Ordered conformational change in the protein backbone: prediction of conformationally variable positions from sequence and low-resolution structural data. Proteins 2008;72:74-87.
67. Liu YC, Yang MH, Lin WL, Huang CK, Oyang YJ. A sequence-based hybrid predictor for identifying conformationally ambivalent regions in proteins. BMC Genom 2009;10 (Suppl 3):S22.
68. Bryan PN, Orban J. Proteins that switch folds. Curr Opin Struc Biol 2010;20:482-488.
69. Teilum K, Olsen JG, Kragelund BB. Protein stability, flexibility and function. BBA Proteins Proteom 2011;1814:969-976.
70. Gill JK, Dhankher P, Sheppard TD, Sher E, Millar NS. A series of α7 nicotinic acetylcholine receptor allosteric modulators with close chemical similarity but diverse pharmacological properties. Mol Pharmacol 2012; 81:710-718.
71. Melancon BJ, Hopkins CR, Wood MR, Emmite KA, Niswender CM, Christopoulos A, Conn PJ, Lindsley CW. Allosteric modulation of seven transmembrane spanning receptors: theory, practice and opportunities for central nervous system drug discovery. J Med Chem 2012;55:1445-1464.
72. Wood MR, Hopkins CR, Brogan JT, Conn PJ, Lindsley CW. "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry 2011;50:2403-2410.